主记录
GSK1059615
- CAS
- 958852-01-2
- PubChem CID
- 23582824
- SMILES
- C1=CC2=NC=CC(=C2C=C1/C=C\3/C(=O)NC(=O)S3)C4=CC=NC=C4
- 分子式
- C18H11N3O2S
- 分子量
- 333.372
- 精确分子量
- 333.0572
- InChI
- InChI=1S/C18H11N3O2S/c22-17-16(24-18(23)21-17)10-11-1-2-15-14(9-11)13(5-8-20-15)12-3-6-19-7-4-12/h1-10H,(H,21,22,23)/b16-10-
- InChIKey
- QDITZBLZQQZVEE-YBEGLDIGSA-N
- LogP
- 3.6207
- TPSA
- 71.95
名称与别名
- GSK1059615
- 958852-01-2
- GSK-1059615
- GSK 1059615
- GSK-615
- GSK615
- UNII-07YMO87363
- RefChem:144501
- C18H11N3O2S
- cc-609
- CHEBI:71955
- DTXSID00242004
- MFCD18074517
- QDITZBLZQQZVEE-YBEGLDIGSA-N
- GTPL9826
- orb1305601
- SCHEMBL1805557
- 07YMO87363
- CHEMBL3544966
- SCHEMBL29351551
- DTXCID60164495
- GSK 1059615 sodium salt hydrate
- PI3K Inhibitor GSK1059615
- GLXC-06054
- EX-A2223
- (Z)-5-((4-(pyridin-4-yl)quinolin-6-yl)methylene)thiazolidine-2,4-dione
- BDBM50623161
- NSC801012
- s1360
- ZINC43176569